

HCV Drug Resistance Advisory Group

Ben Cheng
Forum for Collaborative HIV
Research

THE FORUM FOR
COLLABORATIVE
HIV RESEARCH WWW.HIVFORUM.ORG

*School of Public Health and Health Services
Department of Prevention and Community Health*

The Forum for Collaborative HIV Research is an independent public/private partnership including government agencies, pharmaceutical and diagnostic industries, researchers and clinicians, payors, foundations and the patient advocacy community.

Our mission is to facilitate and enhance HIV research.

The Forum Executive Committee

- Government Agencies
 - US DHHS (NIH, CDC, FDA, HRSA), State Department (OGAC)
 - European Regulatory: EMEA
- Industries
 - Abbott, Bayer Diagnostic, BD Biosciences, Boehringer Ingelheim, Bristol-Myers Squibb, Eurofins-Viralliance, Gilead Sciences, GlaxoSmithKline, Incyte, Merck, Monogram BioScience, Panacos, Roche Laboratories, Roche Molecular Systems, Pfizer, Schering-Plough, Tibotec, Trimeris, VIRxSYS
- Payors
 - Kaiser Permanente
- Academia
 - US and Europe
- Providers
- Patient Advocacy
 - US and Europe
- Foundations & Organizations
 - Gates Foundation, amfAR, IAS, ANAC

History of the Forum

- February 1996 - Vice President Al Gore held a meeting with leaders from the pharmaceutical industry, community advocates and government officials to discuss further steps in the development of ARVs to determine the best uses and long-term effectiveness of these drugs
- At Al Gore's request, the Keystone Center held a series of meetings between representatives from the pharmaceutical industry, public and private payors, healthcare delivery system groups, government agencies, patient advocacy groups and clinical research centers to discuss HIV medical management issues and the development of a framework for collaboration

History of the Forum

- As a result of these meetings, a report was generated proposing the development of a project to continue the discussion amongst all of the stakeholders regarding the development of long-term strategies for the optimal use of ARVs for HIV infection
- The report was presented to Al Gore on August 2, 1996 with a recommendation that such work and guidance continue through the creation of the Forum for Collaborative HIV Research
- The Forum was officially started in March 1, 1997

Some Past Projects

- Pediatric Formulations for Antiretroviral Therapies
- Establishing Collaborative Networks Amongst HIV Training Programs in Africa
- HIV Therapeutic Vaccines: Moving the Field Forward
- Quality of HIV Care: Closing the Gap
- HIV Infection, HIV Treatment and the Risk of Cardiovascular Disease: An Independent Review of Ongoing Studies
- Linkage and Integration of HIV Testing, Prevention and Care Services
- Sex and Gender Issues in the Management of HIV Care
- Racial and Ethnic Minority Issues in the Management of HIV Care, Prevention and Research
- Monitoring Long-Term Toxicities of HIV Treatment

Ongoing Projects

- Accessing Drugs for Clinical Research in Resource-Limited Settings
- Biomedical Interventions for HIV Prevention
- Chemokine Antagonist Working Group
- HIV/TB Co-Infection
- Long-Term Monitoring of Treatment-Related Adverse Events in the Resource-Limited Setting
- Pediatric Diagnosis and Monitoring Working Group
- Standardization and Clinical Relevance of HIV Drug Resistance Testing
- Transfer of HIV Monitoring Technologies into Resource-Limited Settings

New Projects for 2007

- HCV Drug Resistance Advisory Group
- Rethinking the Approach to Expanded Access Programs
- Immune Activation and HIV Infection
- Statistics and Epidemiologic Methods in HIV Research
- New Approaches to Study Designs for Antiretroviral Therapy

Project Selection: Putting Projects on the Table

- Executive committee members
- New projects growing out of previous projects
- Forum partners
- Community at large

HCV DRAG

- Proposal presented at the Executive Committee's annual meeting
- Consensus that the Forum model be extended to HCV Drug Resistance
 - Independent funding for this project need to be obtained

The Forum Model - How We Work

- Working Groups/Meetings include representatives from the patient advocacy community, academia, government agencies and the pharmaceutical and diagnostic industries
- Everyone brings particular expertise and actively participates
 - “agendas” are left at the door
- By-invitation meetings:
 - Open, confidential, discussions
 - No public reports until there is sign off from the whole group
- Meeting materials and presentations will be posted as PDFs on the Forum’s website
 - Opt-out: please advise if presentation includes confidential information to be removed prior to posting

What Makes the Forum Successful

- Partnership
- Independence
- Neutral platform for discussion
- Ability to move quickly and strategically
- Working with what's out there
 - Not repeating or duplicating what is already happening

Special Thanks

- The Planning Committee:
 - Charles Boucher
 - Nick Cammack
 - Ben Cheng
 - Dale Kempf
 - Ann Kwong
 - Veronica Miller
 - Jules O'Rear
 - Neil Parkin
 - Chip Schooley
- Linda Onaga and Meagan Lyon
- Debbie Cooke